Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.33 |
| ▸ | KDM6B | O15054 | 2/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18858144 | 0.82 | MAPK8 (0.34) | KDM4CKDM6BKDM4DEGFREGLN3 | |
| SCHEMBL18858140 | 0.81 | HDAC1 (0.43) | HDAC1HDAC3KDM4CKDM6BKDM4D | |
| SCHEMBL18858135 | 0.80 | KDM4C (0.40) | KDM4CKDM6BKDM4DEGLN3ALDH1A1 | |
| SCHEMBL18858141 | 0.79 | HDAC1 (0.47) | HDAC1HDAC3 | |
| SCHEMBL27147974 | 0.66 | KDM4C (0.43) | HDAC1HDAC3KDM4CKDM6BKDM4D | |
| SCHEMBL10206277 | 0.65 | CA1 (0.46) | HDAC1HDAC3KDM4CKDM6BKDM4D | |
| SCHEMBL5767632 | 0.65 | NOTUM (0.57) | HDAC1HDAC3ALDH1A1 | |
| SCHEMBL18858136 | 0.61 | MAPK8 (0.39) | HDAC1HDAC3KDM4CKDM6BKDM4D | |
| SCHEMBL9017891 | 0.60 | HDAC1 (0.49) | HDAC1HDAC3KDM4CKDM6BKDM4D | |
| SCHEMBL18857773 | 0.60 | KDM4C (0.46) | HDAC1HDAC3KDM4CKDM6BKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134662-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges Antibiotics and Myelin Disease Therapy | TPAT IP LLC | 2018-05-17 | — | — | US | disclosed |
| US-9867813-B2 | Aminopyridine based buffers with wide buffering ranges, antibiotics and myelin disease therapy | TPAT IP LLC | 2018-01-16 | — | — | US | disclosed |
| US-20170135998-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges, Antibiotics and Myelin Disease Therapy | TPAT IP LLC | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134662-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges Antibiotics and Myelin Disease Therapy | AQP4, PMP22, MAG | HDAC1 2045/4885HDAC3 2417/4885KDM4C 2547/4885 |
| US-20170135998-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges, Antibiotics and Myelin Disease Therapy | AQP4, PMP22, MAG | HDAC1 2464/4885HDAC3 2650/4885KDM4C 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.